Navigation Links
Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
Date:10/29/2007

Optivus Proton Therapy, Inc. Teams with Parsons Commercial Technology Group

Inc. to Produce Proton Beam Treatment Centers Globally

LOS ANGELES, Oct. 29 /PRNewswire/ -- Yesterday, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), Optivus Proton Therapy, Inc. (Optivus(R)) and Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, announced a historic teaming agreement has been formalized between the two companies to globally produce turn-key proton beam therapy centers.

"The agreement between the teams of Optivus and Parsons will assure our clients that their proton system will be completed on time by the most expert team in the field," said Jon Slater, Optivus President and CEO. "This is a win/win/win situation for Optivus, Parsons and our clients."

Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.

"Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio," said John Small, Parsons Group President.

Optivus was formed by the engineers who designed and installed the world's first and most successful hospital-based proton center at Loma Linda University Medical Center in Loma Linda, California. The facility commissioned and maintained by Optivus has enjoyed more success than all other comparable competitors' systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.

"Interest in the development of proton treatment centers has grown at an enormous rate in recent years and can largely be attributed to our successes," Slater said. "This development will further reinforce our position as the global leader in proton therapy technology," he added.

The Southern California-based Optivus Parsons team will meet the market demand for the development of proton therapy using Optivus' patented and proven technology.

"The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity," said Slater.

"The Optivus Parsons teaming agreement is a milestone for both companies," said Small. "We share Optivus' dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they've set the gold standard."

Representatives from Parsons will be in attendance at the Optivus booth 501 during ASTRO for Q & A.

ABOUT OPTIVUS AND PARSONS

Optivus Proton Therapy, Inc. is a pioneer in the field of proton therapy technology. Optivus' patented, FDA-cleared modular Proton Beam Therapy System (PBTS), the Conforma 3000(R), leads the industry in patient throughput, highest operational reliability and safety. To date, the Optivus system has delivered nearly half a million individual patient treatments with a perfect safety record. For more information about Optivus, visit http://www.optivus.com.

Parsons, celebrating more than 60 years of setting industry standards, is a leader in many diversified markets such as healthcare, education and public buildings, infrastructure, water, transportation, construction, planning, commercial, industrial manufacturing, communications, environmental, life sciences, critical facilities, nuclear and special materials, and homeland security. Parsons provides technical and management solutions to private industrial customers worldwide, as well as federal, regional, and local government agencies. For more information about Parsons, visit http://www.parsons.com.

Contact:

Lisa Pizzi

Marketing Communications

Optivus Proton Therapy, Inc.

909.799.8367 tel.

lpizzi@optivus.com

John Small

Parsons Group President

704.558.4124 tel.

john.small@parsons.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Optivus Proton Therapy, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Historic trial for tuberculosis launched together by leading drug companies
6. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
7. Micro-world of Prehistoric Bacteria Found in Amber
8. Black-Owned Hospital Receives Historical Commemorative Marker
9. Agreement To Speed Up Development of Bird flu vaccine
10. MIOT Hospital Signs Agreement With German Healthcare Facility
11. Indo-Fiji Agreement in Field of Health, Medicine Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology: